Arch Biopartners (FRA:8HA) E10: €0.00 (As of Mar. 2026)


FRA:8HA Arch Biopartners Inc FRA:8HA
8 GF Score
Price €0.50
! 4 Warning Signs
View Full Analysis

What is Arch Biopartners E10?

Arch Biopartners FRA:8HA -15.27% 8 E10 is €0.00 as of Mar. 2026. GuruFocus rates FRA:8HA with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Arch Biopartners's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.004. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -18.60% per year. During the past 5 years, the average E10 Growth Rate was -13.30% per year. During the past 10 years, the average E10 Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Arch Biopartners was 64.30% per year. The lowest was -71.00% per year. And the median was 6.55% per year.

As of today (2026-06-27), Arch Biopartners's current stock price is €0.4965. Arch Biopartners's E10 for the quarter that ended in Mar. 2026 was €0.00. Arch Biopartners's Shiller PE Ratio of today is .


Arch Biopartners  (FRA:8HA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Arch Biopartners E10 Related Terms


Arch Biopartners E10 Historical Data

* Premium members only.

The historical data trend for Arch Biopartners's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Biopartners E10 Chart

Arch Biopartners Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arch Biopartners Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:8HA vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Arch Biopartners's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Shiller PE Ratio falls into.


FRA:8HA
8GF Score
Arch Biopartners Inc FRA:8HA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Biopartners E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arch Biopartners's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.004/132.2623*132.2623
=-0.004

Current CPI (Mar. 2026) = 132.2623.

Arch Biopartners Quarterly Data

per share eps CPI Adj_EPS
201606 -0.002 102.002 -0.003
201609 -0.005 101.765 -0.006
201612 -0.003 101.449 -0.004
201703 -0.002 102.634 -0.003
201706 -0.016 103.029 -0.021
201709 -0.003 103.345 -0.004
201712 -0.004 103.345 -0.005
201803 -0.007 105.004 -0.009
201806 -0.017 105.557 -0.021
201809 -0.007 105.636 -0.009
201812 -0.009 105.399 -0.011
201903 -0.006 106.979 -0.007
201906 -0.001 107.690 -0.001
201909 -0.008 107.611 -0.010
201912 -0.008 107.769 -0.010
202003 -0.001 107.927 -0.001
202006 -0.024 108.401 -0.029
202009 -0.017 108.164 -0.021
202012 -0.017 108.559 -0.021
202103 -0.011 110.298 -0.013
202106 0.009 111.720 0.011
202109 0.007 112.905 0.008
202112 -0.002 113.774 -0.002
202203 -0.006 117.646 -0.007
202206 -0.003 120.806 -0.003
202209 -0.006 120.648 -0.007
202212 -0.024 120.964 -0.026
202303 -0.010 122.702 -0.011
202306 -0.005 124.203 -0.005
202309 0.003 125.230 0.003
202312 -0.009 125.072 -0.010
202403 -0.012 126.258 -0.013
202406 -0.009 127.522 -0.009
202409 -0.012 127.285 -0.012
202412 -0.004 127.364 -0.004
202503 -0.006 129.181 -0.006
202506 -0.003 129.892 -0.003
202509 -0.010 130.287 -0.010
202512 -0.015 130.366 -0.015
202603 -0.004 132.262 -0.004

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.00 mean?
Arch Biopartners (FRA:8HA) has a E10 of €0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Arch Biopartners and its competitors.
Is Arch Biopartners' E10 too high?
Arch Biopartners' current E10 is €0.00. Overall, Arch Biopartners has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Arch Biopartners' E10 compare to VRTX and REGN?
Arch Biopartners' E10 of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Arch Biopartners and its competitors. Arch Biopartners's current E10 is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Biopartners stock overvalued right now?
Arch Biopartners (FRA:8HA) has a current E10 of €0.00. The current E10 is €0.00. Arch Biopartners' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Arch Biopartners (FRA:8HA), the current E10 is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Biopartners Business Description

Other Exchanges ACHFF:USAARCH:Canada
Address 545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic kidney conditions to benefit from novel, targeted therapies that address unmet medical needs in kidney care.
8GF Score

Get the complete analysis for FRA:8HA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.50
Price